Article and Video CATEGORIES
Clinical Trial Spotlight: ALCHEMIST for Early-Stage ALK+ and EGFR Lung Cancer Patients
Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival.
November is Lung Cancer Awareness Month. What are you grateful for?
Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.
[powerpress]
[ratingwidget post_id=0]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Forum Discussions
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
colon cancer and HIV
By Hopish hope on